Welcome to our dedicated page for Xtl Biopharmaceu SEC filings (Ticker: XTLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XTL Biopharmaceuticals Ltd. (XTLB) SEC filings page on Stock Titan provides access to the company’s current reports and other disclosures filed as a foreign private issuer. XTL files reports on Form 6-K under the Securities Exchange Act of 1934, covering corporate events such as shareholder meetings, executive and director changes, subsidiary developments, and material transactions.
In its recent 6-K filings, XTL describes itself as an IP portfolio company that holds 100% of the share capital of The Social Proxy Ltd., a web data company, and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of lupus (SLE). Filings also document the completion of the acquisition of The Social Proxy, the appointment and resignation of senior executives, board changes, and details of shareholder approvals for private placements and compensation arrangements.
Regulatory filings further include Nasdaq-related notices, such as minimum bid price deficiency letters and the company’s responses and options to regain compliance. These disclosures help investors understand XTL’s listing status on the Nasdaq Capital Market and the Tel Aviv Stock Exchange.
On Stock Titan, each new XTLB filing is captured from EDGAR and presented with AI-powered summaries that explain the main points in clear language. Users can quickly see what a particular 6-K covers—whether it is a transaction like the acquisition of The Social Proxy, governance changes, or meeting results—without reading the entire document. This page is a convenient starting point for reviewing XTL’s official communications to regulators and shareholders.
XTL Biopharmaceuticals Ltd. reported that its Extraordinary General Meeting of Shareholders, originally convened on February 17, 2026, was adjourned due to a lack of quorum. The meeting is scheduled to reconvene on February 24, 2026 at 4:00 p.m. Israel time in Tel Aviv.
The reconvened meeting will take place at the offices of the company’s attorneys, Amit, Pollak, Matalon & Co., on Raoul Wallenberg Street in the Ramat Hachayal district. This is a procedural update related to shareholder meeting logistics rather than a change in business or financial results.
XTL Biopharmaceuticals Ltd. reports that it is working to close the proposed acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc., under a binding letter of intent signed on January 13, 2026. The company has also scheduled a shareholders meeting on February 17, 2026 to approve a private placement of up to US$2 million.
Management believes that completing the NeuroNOS acquisition and the private placement will help address its deficiency under Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity. XTL is preparing a plan to regain compliance, but warns there is no assurance the acquisition will close, that shareholders will approve the private placement, or that Nasdaq will accept its plan or maintain the company’s listing.
XTL Biopharmaceuticals Ltd. reports that its wholly owned Israeli subsidiary, The Social Proxy Ltd., has filed a formal application in an Israeli court to commence insolvency proceedings under the Israeli Insolvency and Economic Rehabilitation Law, 2018. This follows the previously reported resignations of the subsidiary’s CEO and CTO.
The parent company is assessing how this development may affect it, including the recoverability of a loan of approximately $1.5 million that XTL extended to The Social Proxy. XTL describes itself as an IP portfolio company that owns 100% of The Social Proxy and has sublicensed an IP portfolio related to hCDR1 for treatment of lupus. The company reiterates standard forward-looking statement cautions regarding risks to its business and future plans.
XTL Biopharmaceuticals Ltd. reported that it received a notification letter from Nasdaq stating that the company no longer meets the continued listing requirement to maintain at least
The notice does not immediately affect XTL’s Nasdaq listing, and its American Depositary Shares will continue to trade under the symbol XTLB. XTL has 45 calendar days, until
XTL Biopharmaceuticals Ltd. reported that it will hold an Extraordinary General Meeting of Shareholders on February 17, 2026 at 4:00 p.m. (Israel time) in Tel Aviv, Israel. The meeting will take place at the offices of its legal counsel, Amit, Pollak, Matalon & Co., on Raoul Wallenberg Street.
To support the meeting, the company is providing a Notice and Proxy Statement, as well as a Proxy Card that allows holders of ordinary shares to vote without attending in person. These documents, furnished as exhibits to the report, describe the proposals to be voted on and explain how shareholders can participate and cast their votes.
XTL Biopharmaceuticals Ltd. has signed a binding letter of intent with Beyond Air, Inc. to acquire Beyond Air’s approximately 85% stake in NeuroNOS Ltd., an Israeli private company developing small‑molecule treatments for autism spectrum disorder, Alzheimer’s disease, brain cancers, and other neurological conditions. If completed, XTL would issue American Depositary Shares so that Beyond Air holds 19.99% of XTL’s outstanding share capital at closing, grant three‑year warrants to help maintain that stake, pay an upfront US$1,000,000 in cash, and pay up to US$5,500,000 in development milestones or, in some cases, a single US$4,000,000 payment.
The LOI also provides for commercial milestone payments between US$2,000,000 and US$12,500,000 linked to net sales of the first NeuroNOS product, and contemplates an offer for other NeuroNOS shareholders to exchange their remaining 15% stake for XTL shares. To help fund the deal and the upfront cash, XTL’s board and audit committee approved a concurrent private placement of up to US$2,000,000 at about US$0.53 per ADS, at a 20% discount, subject to closing of the transaction and various corporate, regulatory, shareholder, and due‑diligence conditions.
XTL Biopharmaceuticals Ltd. reports that Tal Klinger, Chief Executive Officer of its wholly owned Israeli subsidiary Social Proxy Ltd., and Roee Klinger, the subsidiary’s Chief Technology Officer, have resigned from their positions effective immediately as of December 11, 2025. The company states that it is evaluating next steps for the management of Social Proxy Ltd. and plans to provide further updates when appropriate.
XTL Biopharmaceuticals Ltd. reported a leadership change in its finance team. Chief Financial Officer Itay Weinstein will resign effective December 11, 2025, and the company states his resignation is not due to any disagreement with management.
To replace him, the board appointed Niv Segal as Chief Financial Officer. Segal is a CPA with over 12 years of senior financial management experience, including serving as CFO of G.S. Innplay Labs, where he led a $300M acquisition by Playtika, and CFO of Beach Bum, where he managed its $700M acquisition process. He previously served as Group Corporate Controller at Gix Ltd. and began his career at PwC Israel.
XTL Biopharmaceuticals Ltd. announced a board change. Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors due to personal reasons. The company stated his resignation was not the result of any disagreement with the company or its management. Noam Band, the Company’s Chief Executive Officer, was appointed to the Board of Directors in his place, effective immediately.
XTL is an IP portfolio company that owns 100% of The Social Proxy Ltd., a web data company, and has sublicensed an IP portfolio around hCDR1 for treating lupus (SLE). The company trades on Nasdaq (XTLB) and the TASE (XTLB.TA).